☰

Mihaela Obreja, Ph.D. - Publications

Affiliations: 
2010 University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Biostatistics Biology
Tree Info Similar researchers PubMed Report error

29 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Facon T, Niesvizky R, Mateos MV, Siegel D, Rosenbaum C, Bringhen S, Weisel K, Ho PJ, Ludwig H, Kumar S, Wang K, Obreja M, Yang Z, Klippel Z, Mezzi K, et al. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. Blood Advances. 4: 5449-5459. PMID 33166401 DOI: 10.1182/bloodadvances.2020001965  0.319
2020 Leleu X, Beksac M, Chou T, Dimopoulos MA, Yoon S, Prince HM, Pour L, Shelekhova T, Chari A, Khurana M, Obreja M, Qi M, Oriol A, Siegel DSD. Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001. Journal of Clinical Oncology. 38: 8526-8526. DOI: 10.1200/Jco.2020.38.15_Suppl.8526  0.348
2019 Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, Fujii H, Jakubowiak AJ, Rossi D, Sonneveld P. Oprozomib in patients with newly diagnosed multiple myeloma. Blood Cancer Journal. 9: 66. PMID 31420532 DOI: 10.1038/S41408-019-0232-6  0.329
2019 Ghobrial IM, Vij R, Siegel DS, Badros AZ, Kaufman JL, Raje NS, Jakubowiak AJ, Savona MR, Obreja M, Berdeja JG. A Phase 1b/2 Study of Oprozomib in Patients With Advanced Multiple Myeloma and Waldenström Macroglobulinemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31142508 DOI: 10.1158/1078-0432.Ccr-18-3728  0.324
2019 Facon T, Niesvizky R, Weisel K, Bringhen S, Ho PJ, Obreja M, Yang Z, Klippel ZK, Blaedel J, Mezzi K, Siegel DSD. Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): Frailty subgroup analysis from phase III ASPIRE and ENDEAVOR. Journal of Clinical Oncology. 37: 8028-8028. DOI: 10.1200/Jco.2019.37.15_Suppl.8028  0.349
2019 Burke MJ, Ziegler DS, Bautista Sirvent FJ, Attarbaschi A, Gore L, Locatelli F, O'Brien MM, Pauly M, Obreja M, Morris CL, Baruchel A. Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Blood. 134: 3873-3873. DOI: 10.1182/Blood-2019-127350  0.349
2019 Leleu X, Beksac M, Mateos M, Pour L, Weisel K, Coriu D, Obreja M, Goldrick A, Dimopoulos M. Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/ Relapsed or Refractory Multiple Myeloma Clinical Lymphoma Myeloma and Leukemia. 19: e266-e267. DOI: 10.1016/J.Clml.2019.09.440  0.336
2019 Facon T, Niesvizky R, Weisel K, Bringhen S, Ho PJ, Obreja M, Yang Z, Klippel Z, Blaedel J, Mezzi K, Siegel D. CARFILZOMIB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS FROM PHASE 3 ASPIRE AND ENDEAVOR Hemasphere. 3: 635-636. DOI: 10.1016/J.Clml.2019.07.299  0.313
2018 Dimopoulos M, Wang M, Maisnar V, Minarik J, Bensinger W, Mateos MV, Obreja M, Blaedel J, Moreau P. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. Journal of Hematology & Oncology. 11: 49. PMID 29615082 DOI: 10.1186/S13045-018-0583-7  0.401
2018 Mateos MV, Goldschmidt H, San-Miguel J, Mikhael J, DeCosta L, Zhou L, Obreja M, Blaedel J, Szabo Z, Leleu X. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Hematological Oncology. PMID 29446103 DOI: 10.1002/Hon.2499  0.387
2018 Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017765032. PMID 29341834 DOI: 10.1200/Jco.2017.76.5032  0.388
2018 Mateos M, Goldschmidt H, San-Miguel JF, Blaedel J, Obreja M, Yang Z, Szabo Z, Leleu X. Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: An Analysis of Overall Survival in Subgroups from the Randomized Phase 3 Aspire and Endeavor Trials Blood. 132: 1964-1964. DOI: 10.1182/Blood-2018-99-112189  0.364
2018 Goldschmidt H, Mateos M, Siegel D, Abonour R, Ludwig H, Obreja M, Iskander KS, Hari P. Overall Survival of Patients Post-Transplant: Study Results from Two Phase 3 Trials ASPIRE and ENDEAVOR Clinical Lymphoma Myeloma and Leukemia. 18: S238-S239. DOI: 10.1016/J.Clml.2018.07.127  0.329
2017 Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. Leukemia. PMID 28439109 DOI: 10.1038/Leu.2017.122  0.378
2017 Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, ... ... Obreja M, et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. British Journal of Haematology. PMID 28211560 DOI: 10.1111/Bjh.14549  0.341
2017 Stewart AK, Siegel D, Ludwig H, Facon T, Goldschmidt H, Jakubowiak AJ, Miguel JFS, Obreja M, Blaedel J, Dimopoulos MA. Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial Blood. 130: 743-743. DOI: 10.1182/Blood.V130.Suppl_1.743.743  0.371
2017 Mateos M, Goldschmidt H, Miguel JFS, Mikhael J, Zhou L, Obreja M, Blaedel J, Iskander KS, Leleu X. Relapsed or Refractory Multiple Myeloma Patients Treated with Second-Line Carfilzomib and Categorized By Prior Exposure to Bortezomib: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials Blood. 130: 1840-1840. DOI: 10.1182/Blood.V130.Suppl_1.1840.1840  0.393
2017 Siegel DS, Oriol A, Rajnics P, Minarik J, Hungria V, Lee JH, Song K, Obreja M, Aggarwal S, Hajek R. Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Clinical Lymphoma Myeloma and Leukemia. 17: e142. DOI: 10.1016/J.Clml.2017.03.256  0.35
2016 Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, ... ... Obreja M, et al. Carfilzomib significantly improves the progression free survival of high-risk patients in multiple myeloma. Blood. PMID 27439911 DOI: 10.1182/Blood-2016-03-707596  0.371
2016 Ludwig H, Dimopoulos MA, Masszi T, Spicka I, Rocafiguera AO, Hajek R, Rosinol L, Siegel DSD, Mihaylov G, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San Miguel J, ... Obreja M, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391). Journal of Clinical Oncology. 34: 8045-8045. DOI: 10.1200/Jco.2016.34.15_Suppl.8045  0.396
2016 Ghobrial IM, Savona MR, Vij R, Siegel DS, Badros A, Kaufman JL, Raje N, Jakubowiak A, Obreja M, Berdeja JG. Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies Blood. 128: 2110-2110. DOI: 10.1182/Blood.V128.22.2110.2110  0.317
2015 Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos M, Wang M, Niesvizky R, Oriol A, ... ... Obreja M, et al. Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391) Blood. 126: 731-731. DOI: 10.1182/Blood.V126.23.731.731  0.365
2015 Palumbo A, Stewart A, Rajkumar S, Masszi T, Spicka I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov G, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, ... ... Obreja M, et al. Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone (KRd) vs Lenalidomide and Dexamethasone (Rd) in Patients (Pts) With Relapsed Multiple Myeloma (RMM) Based on Age: Secondary Analysis From the Phase 3 Study ASPIRE (NCT01080391) Clinical Lymphoma Myeloma and Leukemia. 15: e75-e76. DOI: 10.1016/J.Clml.2015.07.227  0.346
2012 Ballester J, Goldstein T, Goldstein B, Obreja M, Axelson D, Monk K, Hickey M, Iyengar S, Farchione T, Kupfer DJ, Brent D, Birmaher B. Is bipolar disorder specifically associated with aggression? Bipolar Disorders. 14: 283-90. PMID 22548901 DOI: 10.1111/J.1399-5618.2012.01006.X  0.519
2011 Diler RS, Birmaher B, Axelson D, Obreja M, Monk K, Hickey MB, Goldstein B, Goldstein T, Sakolsky D, Iyengar S, Brent D, Kupfer D. Dimensional psychopathology in offspring of parents with bipolar disorder. Bipolar Disorders. 13: 670-8. PMID 22085480 DOI: 10.1111/J.1399-5618.2011.00966.X  0.537
2011 Goldstein TR, Obreja M, Shamseddeen W, Iyengar S, Axelson DA, Goldstein BI, Monk K, Hickey MB, Sakolsky D, Kupfer DJ, Brent DA, Birmaher B. Risk for suicidal ideation among the offspring of bipolar parents: results from the Bipolar Offspring Study (BIOS). Archives of Suicide Research : Official Journal of the International Academy For Suicide Research. 15: 207-22. PMID 21827311 DOI: 10.1080/13811118.2011.589699  0.549
2011 Bella T, Goldstein T, Axelson D, Obreja M, Monk K, Hickey MB, Goldstein B, Brent D, Diler RS, Kupfer D, Sakolsky D, Birmaher B. Psychosocial functioning in offspring of parents with bipolar disorder. Journal of Affective Disorders. 133: 204-11. PMID 21463899 DOI: 10.1016/J.Jad.2011.03.022  0.446
2010 Birmaher B, Axelson D, Goldstein B, Monk K, Kalas C, Obreja M, Hickey MB, Iyengar S, Brent D, Shamseddeen W, Diler R, Kupfer D. Psychiatric disorders in preschool offspring of parents with bipolar disorder: the Pittsburgh Bipolar Offspring Study (BIOS). The American Journal of Psychiatry. 167: 321-30. PMID 20080982 DOI: 10.1176/Appi.Ajp.2009.09070977  0.56
2009 Birmaher B, Axelson D, Monk K, Kalas C, Goldstein B, Hickey MB, Obreja M, Ehmann M, Iyengar S, Shamseddeen W, Kupfer D, Brent D. Lifetime psychiatric disorders in school-aged offspring of parents with bipolar disorder: the Pittsburgh Bipolar Offspring study. Archives of General Psychiatry. 66: 287-96. PMID 19255378 DOI: 10.1001/Archgenpsychiatry.2008.546  0.56
Show low-probability matches.